Refractory delirium tremens treated with propofol: A case series

Critical Care Medicine

Volumn 28, Issue 6, 2000, Pages 1781-1784

  McCowan, Christy ^a   Marik, Paul ^b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

Alcohol withdrawal; Benzodiazepines; Delirium tremens; Lorazepam; N methyl D aspartate; Propofol; aminobutyric acid

Indexed keywords

BENZODIAZEPINE DERIVATIVE; LORAZEPAM; PROPOFOL;

ADULT; ALCOHOL WITHDRAWAL; ARTICLE; CASE REPORT; DELIRIUM TREMENS; HUMAN; INTENSIVE CARE; MALE; MORTALITY; PRIORITY JOURNAL; TREATMENT INDICATION; TREATMENT PLANNING;

EID: 0033931334     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200006000-00014     Document Type: Article

References (44)

1. 1. Grant FF: Alcohol consumption, alcohol abuse and alcohol dependence: The United States as an example. Addiction 1994; 89: 1357-1365
2. 2. Eighth Special Report to the U. S. Congress on Alcohol and Health. Rockville, MD, National Institute on Alcohol Abuse and Alcoholism. DHHS Publication No. ADM 281-91-0003, 1993
3. 3. Chiang WK, Goldfrank LR: Substance withdrawal. Emerg Med Clin North Am 1990; 8:613-631
4. 4. Turner RC, Lichstein PR, Peden JGJ, et al: Alcohol withdrawal syndromes: A review of pathophysiology, clinical presentation, and treatment. J Gen Intern Med 1989; 4:432-444
5. 5. Wolf KM, Shaughnessy AF, Middleton DB: Prolonged delirium tremens requiring massive doses of medication. J Am Board Fam Pract 1993; 6:502-504
6. 6. Adinoff B: Double-blind study of alprazolam, diazepam, clonidine, and placebo in the alcohol withdrawal syndrome: Preliminary findings. Alcohol Clin Exp Res 1994; 18: 873-878
7. 7. Grippen DW: Strategies for managing delirium tremens in the ICU. J Crit Illness 1997; 12:140-149
8. 8. Coomes TR, Smith SW: Successful use of propofol in refractory delirium tremens. Ann Emerg Med 1997; 30:825-828
9. 9. Ermakov S, Crippen DW: Continuous propofol infusion for sedation in delirium tremens. Crit Care Med 1994; 20(Suppl):S37
10. 10. Tsai G, Gastfriend DR, Coyle JT: The glutamatergic basis of human alcoholism. Am J Psychiatry 1995; 152:332-340
11. 11. Gianoulakis C, Angelogianni P, Meany M: Endorphins in individuals with high and low risk for development of alcoholism. In: Opoids, Bulemia and Alcohol Abuse and Al coholism. Reid LD (Ed.) New York. Springer-Verlag, 1990, pp 229
12. 12. Mihic SJ, Ye Q, Wick MJ, et al: Sites of alcohol and volatile anaesthetic action on GABA(A) and glycine receptors. Nature 1997; 389:385-389
13. 13. Whitten RJ, Maitra R, Reynolds JN: Modulation of GABA-A receptor function by alcohols: Effects of subunit composition and differential effects of ethanol. Alcohol Clin Exp Res 1996; 20:1313-1319
14. 14. Tsai G, Coyle JT: The role of glutamatergic neurotransmission in the pathophysiology of alcoholism. Annu Rev Med 1998; 49:173-184
15. 15. Hara M, Kai Y, Ikemoto Y: Propofol activates GABA-A receptor-chloride ionophore complex in dissociated hippocampal pyramidal neurons of the rat. Anesthesiology 1993; 79: 781-788
16. 16. Saitz R, O'Malley SS: Pharmacotherapies for alcohol abuse: Withdrawal and treatment. Med Clin North Am 1997; 81:881-907
17. 17. Smith I, White PF, Nathanson M, et al: Propofol. An update on its clinical use. Anesthesiology 1994; 81:1005-1043
18. 18. Uchida I, Li L, Yang J: The role of the GABA(A) receptor alpha1 subunit N-terminal extracellular domain in propofol potentiation of chloride current. Neuropharmacology 1997; 36:1611-1621
19. 19. Orser BA, Bertlik M, Wang LY, et al: Inhibition by propofol (2,6 di-isopropylphenol) of the N-methyl D-aspartate subtype of glutamate receptor in cultured hippocampal neurones. Br JPharmacol 1995; 116:1761-1768
20. 20. Stecker MM, Kramer TH, Raps EC, et al: Treatment of refractory' status epilepticus with propofol: Clinical and pharmacokinetic findings. Epilepsia 1998; 39:18-26
21. 21. Kuisma M, Roine RO: Propofol in prehospitai treatment of convulsive status epilepticus. Epilepsia 1995; 36:1241-1243
22. 22. Merigian KS, Browning RG, Leeper KV: Successful treatment of amoxapine-induced refractory status epilepticus with propofol. Acad Emerg Med 1995; 2:128-133
23. 23. Simons PJ, Cockshott ID, Douglas EJ, et al: Disposition in male volunteers of a subanaesthetic intravenous dose of an oil in water emulsion of 14C-propofol. Xenubiotka 1988; 18:429-440
24. 24. Gray PA, Park GR, Cockshott ID, et al: Propofol metabolism in man during the anhepatic and reperfusion phases of liver transplantation. Xenobiotica 1992; 22:105-114
25. 25. Albanese J, Martin C, Lacarelle B, et al: Pharmacokinetics of long-term propofol infusion used for sedation in ICU patients. Anesthesiology 1990; 73:214-217
26. 26. Bailie GR, Cockshott ID, Douglas EJ, et al: Pharmacokinetics of propofol during and after long-term continuous infusion for maintenance of sedation in ICU patients. Br J Anaesth 1992; 68:486-491
27. 27. Harris CE, Grounds RM, Murray AM: Propofol for long-term sedation in the intensive care unit. Anesthesia 1990; 45:366-372
28. 28. Farling PA, Johnston JR, Coppel DL: Propofol infusion for sedation of patients with head injuries in intensive care. Anaesthesia 1989; 44:222-226
29. 29. Aitkenhead AR, Pepperman ML, Willatts SM. et al: Comparison of propofol and midazolam for sedation in critically ill patients. Lancet 1989; ii:704-709
30. 30. Carrasco G, Molina R, Costa J, et al: Propofol vs. midazolam in short-, medium-, and long-term sedation of critically ill patients: A cost-benefit analysis. Chest 1993; 103:557-564
31. 31. Chamorro C, de Latorre FJ, Montero A, et al: Comparative study of propofol versus midazolam in the sedation of critically ill patients: Results of a prospective, randomized, multicenter trial. Crit Care Med 1996; 24:932-939
32. 32. Kress JP, O'Connor MF, Pohlman AS, et al: Sedation of critically ill patients during mechanical ventilation: A comparison of propofol and midazolam. Am J Respir Crit Care Med 1996; 153:1012-1018
33. 33. Barrientos-Vega R, Mar S, Morales-Garcia C, et al: Prolonged sedation of critically ill patients with midazolam or propofol: Impact on weaning and costs. Crit Care Med 1997; 25:33-40
34. 34. Garfield JM, Bukusoglu C: Propofol and ethanol produce additive hypnotic and anesthetic effects in the mouse. Anesth Analg 1996; 83:156-161
35. 35. Currier DS, Bevacqua BK: Acute tachyphylaxis to propofol sedation during ethanol withdrawal. J Clin Anesth 1997; 9:420-423
36. 36. Valente JF, Anderson CL, Branson RD, et al: Disadvantages of prolonged propofol sedation in the critical care unit. Crit Care Med 1994; 22:710-712
37. 37. Sanchez IRJ, Caballero-Cubedo RE, Perez-Vela JL, et al: Propofol versus midazolam: Safety and efficacy for sedating the severe trauma patient. Anesth Analg 1998; 86: 1219-1224
38. 38. Mateu J, Barrachina F: Hypertriglyceridaemia associated with propofol sedation in critically ill patients. Intensive Care Med 1996; 22:834-835
39. 39. Eddleston JM, Shelly MP: The effect on serum lipid concentrations of a prolonged infusion of propofol: Hypertriglyceridaemia associated with propofol administration. Intensive Care Med 1991; 17:424-426
40. 40. Lowrey TS, Dunlap AW, Brown RO, et al: Pharmacologic influence on nutrition support therapy: Use of propofol in a patient receiving combined enteral and parenteral nutrition support. Nutr Clin Pract 1996; 11: 147-149
41. 41. Mirenda J, Broyles G: Propofol as used for sedation in the ICU. Chest 1995; 108: 539-548
42. 42. Metkus AP, Trabulsy PP, Schlobohm RS, et al: A firefighter with pancreatitis. Lancet 1996; 348:1702-1728
43. 43. Possidente CJ, Rogers FB, Osler TM, et al: Elevated pancreatic enzymes after extended propofol therapy. Pharmacotherapy 1998; 18:653-655
44. 44. Leisure GS, O'Flaherty J, Green L, et al: Propofol and postoperative pancreatitis. Anesthesiology 1996; 84:224-227